Aethlon Medical (AEMD) furnishes updated corporate investor presentation

Rhea-AI Filing Summary

Aethlon Medical, Inc. furnished an updated corporate investor presentation that may be used in conferences and investor meetings. The presentation, dated August 20, 2025, is available on the company’s website and is attached as Exhibit 99.1. The company emphasizes that this material is being provided under Regulation FD as “furnished, not filed,” meaning it is not subject to certain liability provisions of the securities laws and is not automatically incorporated into other SEC filings unless specifically referenced. This update is primarily an informational disclosure for investors and other stakeholders, rather than a report of new financial results or a major transaction.

false 0000882291 0000882291 2025-08-21 2025-08-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 21, 2025

Aethlon Medical, Inc.

(Exact name of registrant as specified in its charter)

Nevada	001-37487	13-3632859
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

11555 Sorrento Valley Road, Suite 203 San Diego, California	92121
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (619) 941-0360

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		AEMD		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosures.

On August 20, 2025, Aethlon Medical, Inc. (the “Company”) made available an updated corporate presentation (the “Presentation”) that may be used by the Company in connection with presentations at conferences and investor meetings.  The Presentation can be found on the Company’s website, www.aethlonmedical.com.  The Presentation is furnished as Exhibit 99.1 hereto.

The information in the Presentation is being furnished, not filed, pursuant to this Item 7.01. Accordingly, the information in the Presentation will not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.  The furnishing of the information in this Current Report on Form 8-K with respect to the Presentation is not intended to, and does not, constitute a determination or admission by the Company that the information in this Current Report on Form 8-K with respect to the Presentation is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.

Item 9.01 Financial Statements and Exhibits. 

(d) Exhibits

Exhibit Number		Description
99.1		Presentation Materials
104		Cover Page Interactive Data File (embedded within the inline XBRL Document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 21, 2025	Aethlon Medical, Inc.
	By:	/s/ James B. Frakes
	Name: Title:	James B. Frakes Chief Executive Officer and Chief Financial Officer

3

FAQ

What did Aethlon Medical (AEMD) disclose in this 8-K filing?

Aethlon Medical disclosed that it has made available an updated corporate presentation for use at conferences and investor meetings. The presentation is attached as Exhibit 99.1 and is also accessible on the company’s website.

Is the new Aethlon Medical (AEMD) presentation considered filed with the SEC?

No. The company states that the information in the presentation is being furnished, not filed under Regulation FD. As a result, it is not deemed filed for purposes of Section 18 of the Exchange Act and is not automatically incorporated into other filings unless specifically referenced.

Where can investors find Aethlon Medical’s updated corporate presentation?

The updated presentation is attached as Exhibit 99.1 to this report and can also be found on Aethlon Medical’s website at www.aethlonmedical.com, as noted in the disclosure.

Does this Aethlon Medical 8-K announce new financial results or major transactions?

No. The 8-K is filed under Item 7.01 Regulation FD Disclosure and focuses on making an updated investor presentation available. It does not describe new earnings figures or major corporate transactions in the text provided.

Who signed the Aethlon Medical (AEMD) 8-K related to the presentation?

The report was signed on behalf of Aethlon Medical, Inc. by James B. Frakes, who is identified as the company’s Chief Executive Officer and Chief Financial Officer.

What exhibits are included with this Aethlon Medical 8-K filing?

The exhibits listed are Exhibit 99.1, which contains the presentation materials, and Exhibit 104, the cover page interactive data file embedded within the inline XBRL document.